A composite liquid biomarker for non-invasive diagnosis of resectable
pancreatic ductal adenocarcinoma
Ann Oncol
2018
29
Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
BMC Cancer
2018
18
1
1298
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.
Front Immunol
2018
9
Increased risk of candidemia in patients with necrotising pancreatitis infected with candida species.
Pancreatology
2018
18
6
630-634
Management of occluded self-expanding biliary metal stents in malignant biliary disease.
Hepatobiliary Pancreat Dis Int
2018
17
1
49-54
Distinct Pathogenesis of Pancreatic Cancer Microvesicle-Associated Venous Thrombosis Identifies New Antithrombotic Targets In Vivo.
Arterioscler Thromb Vasc Biol
2018
38
4
772-786
Genome-wide association study identifies inversion in the CTRB1-CTRB2 locus to modify risk for alcoholic and non-alcoholic chronic pancreatitis.
Gut
2018
67
10
1855-1863